I-Mab
NASDAQ:IMAB
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
0.9397
2.37
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
I-Mab
Minority Interest
I-Mab
Minority Interest Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Minority Interest | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
I-Mab
NASDAQ:IMAB
|
Minority Interest
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
||
Beigene Ltd
HKEX:6160
|
Minority Interest
ÂĄ0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
||
Akeso Inc
HKEX:9926
|
Minority Interest
-ÂĄ87.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
||
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Minority Interest
ÂĄ183.1m
|
CAGR 3-Years
90%
|
CAGR 5-Years
55%
|
CAGR 10-Years
N/A
|
||
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
|
Minority Interest
ÂĄ14.2m
|
CAGR 3-Years
39%
|
CAGR 5-Years
2%
|
CAGR 10-Years
0%
|
||
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Minority Interest
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
I-Mab
Glance View
I-Mab operates as a clinical stage biopharmaceutical company. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2020-01-17.